Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniel Long
Institution:
BioCryst Pharmaceuticals (United States)
Observed institutions:
BioCryst Pharmaceuticals (United States),
Christ Hospital,
Michigan State University,
University of Toledo
OpenAlex ID:
A5113581493
Interim outcomes of mechanical thrombectomy for deep vein thrombosis from the All-Comer CLOUT Registry
2022
·
David J. Dexter
, Herman Kado
, et al.
·
Journal of Vascular Surgery Venous and Lymphatic Disorders
·
52
PDF
Mechanical Thrombectomy vs. Pharmacomechanical Catheter Directed Thrombolysis for the Treatment of Iliofemoral Deep Vein Thrombosis: A Propensity Score Matched Exploratory Analysis of 12 Month Clinical Outcomes
2023
·
Steven Abramowitz
, Matthew C. Bunte
, et al.
·
European Journal of Vascular and Endovascular Surgery
·
36
PDF
Six-Month Deep Vein Thrombosis Outcomes by Chronicity: Analysis of the Real-World ClotTriever Outcomes Registry
2023
·
Steven D. Abramowitz
, Herman Kado
, et al.
·
Journal of Vascular and Interventional Radiology
·
25
Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis
2025
·
Rany Aburashed
, Ansam Eghzawi
, et al.
·
Neurology International
·
12
PDF
CNS-disseminated Angiostrongylus cantonensis mimicking atypical demyelinating disease
2019
·
Daniel Long
, Kemar Green
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
5
PDF
Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review
2010
·
Rachna Raman
, Philip D. Leming
, et al.
·
Oncology Reviews
·
3
Interim outcomes of mechanical thrombectomy for deep vein thrombosis from the All-Comer CLOUT Registry
2022
·
David J. Dexter
, Herman Kado
, et al.
·
European Journal of Vascular and Endovascular Surgery
·
2
Septic Thromboembolic Stroke via Atrial-Esophageal Fistula as a Delayed Complication of Cardiac Ablation (P6.018)
2016
·
Talal Derani
, Saqib Chaudhry
, et al.
·
Neurology
·
2
HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
2025
·
Jolanta Bernatoniene
, Melisande Bourgoin-Heck
, et al.
·
Journal of Allergy and Clinical Immunology
·
1
PDF
Malignant cerebral edema secondary to hyperammonemia in setting of acquired carnitine deficiency
2020
·
Daniel Long
, Talal Derani
, et al.
·
Neurology Clinical Practice
·
1
A plain language summary of oral berotralstat for preventive treatment of hereditary angioedema attacks in children: early safety and efficacy results of the ongoing APeX-P study
2026
·
Jolanta Bernatoniene
, Mélisande Bourgoin-Heck
, et al.
·
Future Rare Diseases
PDF
A Comparative Effectiveness Analysis of Fumarates versus Cladribine in People With MS Transitioning From Anti-CD20 Therapies (P1-20.008)
2026
·
Regina Berkovich
, Daniel Bandari
, et al.
·
Neurology
Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P
2026
·
Jolanta Bernatoniene
, Mélisande Bourgoin-Heck
, et al.
·
Journal of Allergy and Clinical Immunology
PDF
Show more works
View as search
Works count:
13
Citation count:
139
H-index:
5
I10-index:
4
Year
Topic
Type